z-logo
open-access-imgOpen Access
Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
Author(s) -
Shakhnovich Valentina,
Meibohm Bernd,
Rosenberg Amy,
Kierzek Andrzej M.,
Hasenkamp Rachel,
Funk Ryan S.,
Thalhauser Craig J.,
Graaf Piet H.,
Wang YowMing C.,
Hamuro Lora
Publication year - 2020
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/cts.12717
Subject(s) - immunogenicity , medicine , intensive care medicine , clinical trial , tolerability , immunology , pharmacology , immune system , adverse effect
Managing immunogenicity in clinical practice and during drug development was a recent topic at the ASCPT 2019 annual meeting. This commentary expands on the discussion to facilitate a broader engagement across the community. The intent is to provide a rationale for ongoing research into the current gaps in assessing and interpreting immunogenicity in drug development and managing clinical immunogenicity for an approved drug. The following are highlighted: (i) Immunogenicity Considerations in Clinical Practice, (ii) Immunogenicity Testing and Current Limitations, (iii) Immunogenicity Risk Assessment and Mitigation, and (iv) Quantitative Systems Pharmacology (QSP) models of Immunogenicity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here